Epidermal growth factor receptor mutation status and rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiation.

Wachsberger PR, Lawrence RY, Liu Y, Rice B, Daskalakis C, Dicker AP. Epidermal growth factor receptor mutation status and rad51 determine the response of glioblastoma to multimodality therapy with cetuximab, temozolomide, and radiation. Front Oncol. 2013; 3:13.

View in: PubMed